Your browser doesn't support javascript.
loading
Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome.
Meintjes, Graeme; Skolimowska, Keira H; Wilkinson, Katalin A; Matthews, Kerryn; Tadokera, Rebecca; Conesa-Botella, Anali; Seldon, Ronnett; Rangaka, Molebogeng X; Rebe, Kevin; Pepper, Dominique J; Morroni, Chelsea; Colebunders, Robert; Maartens, Gary; Wilkinson, Robert J.
  • Meintjes G; Clinical Infectious Diseases Research Initiative, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. graemein@mweb.co.za
Am J Respir Crit Care Med ; 186(4): 369-77, 2012 Aug 15.
Article en En | MEDLINE | ID: mdl-22700860
ABSTRACT
RATIONALE HIV-tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an immunopathological reaction to mycobacterial antigens induced by antiretroviral therapy. Prednisone reduces morbidity in TB-IRIS, but the mechanisms are unclear.

OBJECTIVES:

To determine the effect of prednisone on the inflammatory response in TB-IRIS (antigen-specific effector T cells, cytokines, and chemokines).

METHODS:

Blood was taken from participants in a randomized placebo-controlled trial of prednisone for TB-IRIS, at 0, 2, and 4 weeks. Participants received prednisone at a dosage of 1.5 mg/kg/day for 2 weeks followed by 0.75 mg/kg/day for 2 weeks, or placebo at identical dosages. MEASUREMENTS AND MAIN

RESULTS:

Analyses included IFN-γ enzyme-linked immunospot (ELISPOT), reverse transcription-polymerase chain reaction on peripheral blood mononuclear cells after restimulation with heat-killed Mycobacterium tuberculosis, Luminex multiplex cytokine analysis of corresponding tissue culture supernatants, and Luminex multiplex cytokine analysis of serum. Fifty-eight participants with TB-IRIS (31 receiving prednisone, 27 receiving placebo) were included. In serum, significant decreases in IL-6, IL-10, IL-12 p40, tumor necrosis factor-α, IFN-γ, and IFN-γ-induced protein-10 concentrations during prednisone, but not placebo, treatment were observed. No differences in ELISPOT responses comparing prednisone and placebo groups were shown in response to ESAT-6 (early secreted antigen target-6), Acr1, Acr2, 38-kD antigen, or heat-killed H37Rv M. tuberculosis. Purified protein derivative ELISPOT responses increased over 4 weeks in the prednisone group and decreased in the placebo group (P = 0.007).

CONCLUSIONS:

The beneficial effects of prednisone in TB-IRIS appear to be mediated via suppression of predominantly proinflammatory cytokine responses of innate immune origin, not via a reduction of the numbers of antigen-specific T cells in peripheral blood.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Prednisona / Síndrome Inflamatorio de Reconstitución Inmune / Glucocorticoides Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Año: 2012 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Prednisona / Síndrome Inflamatorio de Reconstitución Inmune / Glucocorticoides Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male Idioma: En Año: 2012 Tipo del documento: Article